# Tamsulosin

## Harnalidge OCAS 0.4mg prolonged release

| TAH Drug Code      | [**OHAR4**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OHAR4)                                                                                                                                                                        |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of signs and symptoms of benign prostatic hyperplasia (BPH)                                                                                                                                                                             |
| Dosing             | Benign prostatic hyperplasia: Oral, Initial and maintenance: 0.4 mg once daily, may increase to 0.8 mg once daily.                                                                                                                                |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                     |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                     |
| Contraindications  | Hypersensitivity to tamsulosin or any component of the formulation                                                                                                                                                                                |
| Adverse Effects    | Cardiovascular: Orthostatic hypotension (6% to 19%) Central nervous system: Headache (19% to 21%), dizziness (15% to 17%) Genitourinary: Abnormal ejaculation (8% to 18%) Respiratory: Rhinitis (13% to 18%) Miscellaneous: Infection (9% to 11%) |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Low Risk                                                                                                                                                                                            |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                      |

